Journal of Current Glaucoma Practice

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  18 (2024)
Volume  17 (2023)
Volume  16 (2022)
Volume  15 (2021)
Volume  14 (2020)
Volume  13 (2019)
Volume  12 (2018)
Volume  11 (2017)
Volume  10 (2016)
Volume  9 (2015)
Volume  8 (2014)
Volume  7 (2013)
Volume  6 (2012)
Related articles

VOLUME 15 , ISSUE 2 ( May-August, 2021 ) > List of Articles

ORIGINAL RESEARCH

Sociodemographic and Economic Factors in Outcomes of Tube Shunts for Neovascular Glaucoma

Wesam S Shalaby, Amirmohsen Arbabi, Jonathan S Myers, Marlene R Moster, Reza Razeghinejad, L Jay Katz, Aakriti G Shukla

Citation Information : Shalaby WS, Arbabi A, Myers JS, Moster MR, Razeghinejad R, Katz LJ, Shukla AG. Sociodemographic and Economic Factors in Outcomes of Tube Shunts for Neovascular Glaucoma. J Curr Glaucoma Pract 2021; 15 (2):70-77.

DOI: 10.5005/jp-journals-10078-1303

License: CC BY-NC 4.0

Published Online: 30-09-2021

Copyright Statement:  Copyright © 2021; The Author(s).


Abstract

Importance: Few studies have analyzed associations between sociodemographic factors and neovascular glaucoma (NVG) outcomes. Aim and background: To determine the potential impact of sociodemographic and economic factors on the NVG tube shunt surgery outcomes. Design: Retrospective, single-center, comparative case series. Participants: Consecutive patients who underwent tube shunt surgery for NVG and had ≥6 months of follow-up. Materials and methods: Regional average adjusted gross income (AGI) was determined by cross-referencing self-reported residential zip codes with average AGI per zip code supplied by the Internal Revenue Service. Two groups were created: (1) lower-income: individuals from neighborhoods with the lowest 10% of AGI (near the United States poverty line), (2) higher-income: the remaining 90% of individuals. Main outcome measures: Visual acuity (VA), intraocular pressure (IOP), and glaucoma medication number at 6 months and the most recent visit. Results: The mean annual AGI in the higher-income group (130 patients) was $69,596 ± 39,700 and the lower-income group (16 patients) was $27,487 ± 1,600 (p < 0.001). Age, sex, distance to the clinic, language, and all baseline clinical variables (including VA and IOP) were comparable between groups. Lower-income was associated with non-white race (81.3 vs 52.3%; p = 0.024). At month 6, VA in the lower-income group [median: HM (20/70–NLP)] was worse than the higher-income group [median: CF (20/25–NLP)] (log MAR VA: 2.32 ± 0.8 vs 1.77 ± 1.1; p = 0.02); these trends persisted through the most recent visit (p = 0.043). Follow-up IOP and medications were similar between groups. Conclusions and relevance: Lower-income may be associated with worse VA outcomes following NVG tube shunt surgery.

HTML PDF Share
  1. Hayreh SS. Neovascular glaucoma. Prog Retin Eye Res 2007;26(5): 470–485.
  2. Olmos LC, Lee RK. Medical and surgical treatment of neovascular glaucoma. Int Ophthalmol Clin 2011;51(3):27–36.
  3. Netland PA. The Ahmed glaucoma valve in neovascular glaucoma (An AOS Thesis). Trans Am Ophthalmol Soc 2009;107: 325–342.
  4. Sidoti PA, Dunphy TR, Baerveldt G, et al. Experience with the Baerveldt glaucoma implant in treating neovascular glaucoma. Ophthalmology 1995;102(7):1107–1118.
  5. Budenz DL, Barton K, Gedde SJ, et al. Five-year treatment outcomes in the Ahmed Baerveldt comparison study. Ophthalmology 2015;122(2):308–316.
  6. Alkawas AA, Shahien EA, Hussein AM. Management of neovascular glaucoma with panretinal photocoagulation, intravitreal bevacizumab, and subsequent trabeculectomy with mitomycin C. J Glaucoma 2010;19(9):622–626.
  7. Dickman SL, Himmelstein DU, Woolhandler S. Inequality and the health-care system in the USA. Lancet 2017;389(10077): 1431–1441.
  8. Hargraves JL, Hadley J. The contribution of insurance coverage and community resources to reducing racial/ethnic disparities in access to care. Health Serv Res 2003;38(3):809–829.
  9. Nelson A. Unequal treatment: confronting racial and ethnic disparities in health care. J Natl Med Assoc 2002;94(8):666–668.
  10. Manuel JI. Racial/ethnic and gender disparities in health care use and access. Health Serv Res 2018;53(3):1407–1429.
  11. Waldron H. Trends in mortality differentials and life expectancy for male social security-covered workers, by socioeconomic status. Soc Secur Bull 2007;67(3):1–28.
  12. Chetty R, Stepner M, Abraham S, et al. The association between income and life expectancy in the United States, 2001-2014. JAMA 2016;315(16):1750–1766.
  13. Arora S, Kurji AK, Tennant MT. Dismantling sociocultural barriers to eye care with tele-ophthalmology: lessons from an Alberta Cree community. Clin Invest Med 2013;36(2):E57–E63.
  14. Zambelli-Weiner A, Crews JE, Friedman DS. Disparities in adult vision health in the United States. Am J Ophthalmol 2012;154(6 Suppl):S23–30.e1.
  15. Chou CF, Barker LE, Crews JE, et al. Disparities in eye care utilization among the United States adults with visual impairment: findings from the behavioral risk factor surveillance system 2006-2009. Am J Ophthalmol 2012;154(6 Suppl):S45–52.e1.
  16. Hollar MW, Zhang MM, Mawn LA. Ophthalmic disparities in transgender patients. Semin Ophthalmol 2016;31(4):426–431.
  17. Xu D, Uhr J, Patel SN, et al. Sociodemographic factors influencing rhegmatogenous retinal detachment presentation and outcome. Ophthalmol Retina 2021;5(4):337–341.
  18. Patel SN, Wu C, Obeid A, et al. Sociodemographic factors in neovascular age-related macular degeneration. Ophthalmology 2020;127(2):280–282.
  19. Palacios-Barrios EE, Hanson JL. Poverty and self-regulation: Connecting psychosocial processes, neurobiology, and the risk for psychopathology. Compr Psychiatry 2019;90:52–64.
  20. Office of the Assistant Secretary for planning and evaluation. 2020 Poverty Guidelines. https://aspe.hhs.gov/2020-poverty-guidelines. Published 2020. Accessed January 21, 2020.
  21. Ng WS, Agarwal PK, Sidiki S, et al. The effect of socio-economic deprivation on severity of glaucoma at presentation. Br J Ophthalmol 2010;94(1):85–87.
  22. Fraser S, Bunce C, Wormald R, et al. Deprivation and late presentation of glaucoma: case-control study. BMJ 2001;322(7287):639–643.
  23. Obeid A, Gao X, Ali FS, et al. Loss to follow-up in patients with proliferative diabetic retinopathy after panretinal photocoagulation or intravitreal anti-VEGF injections. Ophthalmology 2018;125(9):1386–1392.
  24. Gao X, Obeid A, Adam MK, et al. Loss to follow-up in patients with retinal vein occlusion undergoing intravitreal anti-VEGF injections. Ophthal Surg Lasers Imag Retina 2019;50(3):159–166.
  25. Thangamathesvaran L, Crane E, Modi K, et al. Outcomes of resident-versus attending-performed tube shunt surgeries in a United States residency program. J Curr Glaucoma Pract 2018;12(2):53–58.
  26. Broadway DC, Chang LP. Trabeculectomy, risk factors for failure and the preoperative state of the conjunctiva. J Glaucoma 2001;10(3): 237–249.
  27. Budenz DL, Barton K, Feuer WJ, et al. Treatment outcomes in the Ahmed Baerveldt comparison study after 1 year of follow-up. Ophthalmology 2011;118(3):443–452.
  28. Christakis PG, Kalenak JW, Zurakowski D, et al. The Ahmed versus Baerveldt study: one-year treatment outcomes. Ophthalmology 2011;118(11):2180–2189.
  29. Gedde SJ, Schiffman JC, Feuer WJ, et al. Treatment outcomes in the tube versus trabeculectomy (TVT) study after five years of follow-up. Am J Ophthalmol 2012;153(5):789–803.e2.
  30. Taubenslag KJ, Kammer JA. Outcomes disparities between black and white populations in the surgical management of glaucoma. Semin Ophthalmol 2016;31(4):385–393.
  31. Zheng Y, Lamoureux EL, Chiang PC, et al. Language barrier and its relationship to diabetes and diabetic retinopathy. BMC Public Health 2012;12:781.
  32. Ndiaye-Sow MN, Seck SM, Dieng M, et al. Profile of neovascular glaucoma in senegalese patients. J Fr Ophtalmol 2018;41(7): 637–641.
  33. Lane M, Lane V, Abbott J, et al. Multiple deprivation, vision loss, and ophthalmic disease in adults: global perspectives. Surv Ophthalmol 2018;63(3):406–436.
  34. Group AS, Group AES, Chew EY, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010;363(3):233–244.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.